How Does Wall Street View Abbott Laboratories (ABT)'s Outlook?

💡 Analysts weigh in on the future prospects of Abbott Laboratories, a leading medical device and pharma company.

The healthcare sector has been a bright spot in the market, with many companies delivering strong earnings growth. One such standout is Abbott Laboratories (ABT), a diversified medical device and pharma company. As we approach the midpoint of 2024, investors are eager to know how Wall Street views ABT's outlook.

Industry Trends and ABT's Position

The medical device industry has been experiencing a surge in demand, driven by an aging population and increasing healthcare costs. ABT is well-positioned to capitalize on this trend, with a diverse portfolio of products that cater to various therapeutic areas. The company's recent acquisitions, including the purchase of St. Jude Medical, have expanded its offerings and improved its market share.

Earnings Growth and Valuation

ABT's earnings growth has been impressive, with the company delivering double-digit growth in recent quarters. Analysts expect this trend to continue, with estimates pointing to a 10% increase in earnings per share (EPS) for 2024. The company's valuation is also attractive, with a price-to-earnings (P/E) ratio that's lower than its peers.

Key Drivers of Growth

Several factors are expected to drive ABT's growth in the coming quarters. These include the continued adoption of its medical devices, such as the popular FreeStyle Libre system, and the success of its pharmaceutical products, including the cholesterol-lowering medication, Crenezumab. Additionally, the company's expanding presence in emerging markets is expected to contribute to its growth.

What It Means for Investors